Spots Global Cancer Trial Database for phase 3
Every month we try and update this database with for phase 3 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging | NCT06276465 | Prostatic Cance... | Darolutamide 30... Stereotactic bo... Androgen depriv... | 18 Years - | UNICANCER | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) | NCT02187744 | Early Breast Ca... | PF-05280014 Taxotere® Paraplatin® Trastuzumab-EU Taxotere® Paraplatin® | 18 Years - | Pfizer | |
| Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | NCT03106779 | Chronic Myeloge... | Asciminib Bosutinib | 18 Years - | Novartis | |
| A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer | NCT01767857 | Metastatic Colo... | Xilonix Placebo | 18 Years - | Janssen Research & Development, LLC | |
| A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02) | NCT01989676 | Metastatic Brea... | PF-05280014 Paclitaxel Herceptin® Paclitaxel | 18 Years - | Pfizer | |
| A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide | NCT03495921 | Ewing Sarcoma Ewing Family of... Ewing's Tumor M... Ewing's Sarcoma... Ewing's Tumor R... Rare Diseases Sarcoma Neoplasms, Conn... Neoplasms by Hi... Neoplasms, Bone... Neoplasms, Conn... Sarcoma, Ewing Neoplasms | Vigil Irinotecan Temozolomide | 2 Years - | Gradalis, Inc. | |
| A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone | NCT00457392 | Carcinoma, Non-... | erlotinib sunitinib erlotinib placebo | 18 Years - | Pfizer | |
| Multicenter Phase III Trial of Laparoscopic Sentinel Node Biopsy | NCT01804998 | Early Gastric C... | Laparoscopic Se... Laparoscopy Ass... | 20 Years - 80 Years | National Cancer Center, Korea | |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | NCT03970447 | Glioblastoma | Temozolomide Lomustine Regorafenib Radiation Paxalisib VAL-083 VT1021 Troriluzole ADI-PEG 20 | 18 Years - | Global Coalition for Adaptive Research | |
| Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer | NCT00393939 | Breast Neoplasm... | Sunitinib malat... Taxotere | 18 Years - | Pfizer | |
| Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer | NCT01309126 | Colorectal Canc... | Imprime PGG + c... Cetuximab | 18 Years - | HiberCell, Inc. | |
| Multicenter Phase III Trial of Laparoscopic Sentinel Node Biopsy | NCT01804998 | Early Gastric C... | Laparoscopic Se... Laparoscopy Ass... | 20 Years - 80 Years | National Cancer Center, Korea | |
| Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | NCT02952508 | Waldenstrom Mac... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... Mantle Cell Lym... Diffuse Large B... Central Nervous... | Iopofosine I 13... Iopofosine I 13... Iopofosine I 13... | 18 Years - | Cellectar Biosciences, Inc. | |
| Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma | NCT01875653 | Stage IV Melano... Stage III Melan... | Autologous Dend... Autologous PBMC... | 18 Years - | Lisata Therapeutics, Inc. | |
| Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid | NCT00295646 | Breast Cancer | tamoxifen anastrozole zoledronic acid goserelin | 19 Years - 59 Years | Austrian Breast & Colorectal Cancer Study Group | |
| Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer | NCT01412957 | Metastatic Colo... | Best Supportive... Panitumumab | 18 Years - | Amgen | |
| Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer | NCT01309126 | Colorectal Canc... | Imprime PGG + c... Cetuximab | 18 Years - | HiberCell, Inc. | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China | NCT02966093 | Differentiated ... | Lenvatinib Placebo | 18 Years - | Eisai Inc. | |
| Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | NCT02952508 | Waldenstrom Mac... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... Mantle Cell Lym... Diffuse Large B... Central Nervous... | Iopofosine I 13... Iopofosine I 13... Iopofosine I 13... | 18 Years - | Cellectar Biosciences, Inc. | |
| REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) | NCT05973773 | Advanced or Met... | TAS6417 | 18 Years - | Taiho Oncology, Inc. | |
| A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer | NCT01767857 | Metastatic Colo... | Xilonix Placebo | 18 Years - | Janssen Research & Development, LLC | |
| A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer | NCT00373256 | Breast Neoplasm... | Sunitinib paclitaxel bevacizumab paclitaxel | 18 Years - | Pfizer | |
| Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer | NCT01412957 | Metastatic Colo... | Best Supportive... Panitumumab | 18 Years - | Amgen | |
| A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | NCT04296890 | Epithelial Ovar... Peritoneal Canc... Fallopian Tube ... | Mirvetuximab So... | 18 Years - | ImmunoGen, Inc. | |
| Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer | NCT00393939 | Breast Neoplasm... | Sunitinib malat... Taxotere | 18 Years - | Pfizer | |
| A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) | NCT02187744 | Early Breast Ca... | PF-05280014 Taxotere® Paraplatin® Trastuzumab-EU Taxotere® Paraplatin® | 18 Years - | Pfizer | |
| A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone | NCT00457392 | Carcinoma, Non-... | erlotinib sunitinib erlotinib placebo | 18 Years - | Pfizer | |
| Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer | NCT00393939 | Breast Neoplasm... | Sunitinib malat... Taxotere | 18 Years - | Pfizer | |
| REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) | NCT05973773 | Advanced or Met... | TAS6417 | 18 Years - | Taiho Oncology, Inc. | |
| A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy | NCT01168973 | Non-Small Cell ... | Ramucirumab Placebo (for Ra... Docetaxel | 18 Years - | Eli Lilly and Company | |
| A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | NCT04296890 | Epithelial Ovar... Peritoneal Canc... Fallopian Tube ... | Mirvetuximab So... | 18 Years - | ImmunoGen, Inc. | |
| A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy | NCT01168973 | Non-Small Cell ... | Ramucirumab Placebo (for Ra... Docetaxel | 18 Years - | Eli Lilly and Company | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | NCT01964430 | Pancreatic Neop... Digestive Syste... Neoplasms by Si... Neoplasms Endocrine Gland... Pancreatic Dise... Digestive Syste... Endocrine Syste... Gemcitabine Antimetabolites... | nab-Paclitaxel Gemcitabine | 18 Years - | Celgene | |
| Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC) | NCT00973609 | Colorectal Neop... | 5-Fluorouracil,... 5-Fluorouracil,... 5-Fluorouracil,... | 18 Years - | AIO-Studien-gGmbH | |
| Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels | NCT02375828 | Neonatal Diabet... | Glibenclamide | 1 Month - 18 Years | Assistance Publique - Hôpitaux de Paris | |
| Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | NCT03106779 | Chronic Myeloge... | Asciminib Bosutinib | 18 Years - | Novartis | |
| Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) | NCT01881230 | Breast Tumor Breast Cancer Cancer of the B... Estrogen Recept... HER2- Negative ... Progesterone Re... Recurrent Breas... Stage IV Breast... Triple-negative... Triple-negative... Metastatic Brea... | nab-Paclitaxel Carboplatin Gemcitabine | 18 Years - | Celgene | |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer | NCT02631876 | Epithelial Ovar... Primary Periton... Fallopian Tube ... Ovarian Cancer | Mirvetuximab so... Paclitaxel Pegylated lipos... Topotecan | 18 Years - | ImmunoGen, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
